Lyell Immunopharma, Inc. (LYEL) Institutional Ownership

Ownership Summary

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has 74 institutional investors that have filed 13F reports for the period ending March 2026.

• These investors collectively held 58.1% of Lyell Immunopharma's outstanding shares in March 2026, down from 71.9% in December 2025.
• They increased total shares held in Lyell Immunopharma by 24.55% from the prior quarter, while the number of investors in LYEL decreased 35.09% year over year.
• Of these 74 holders, 43 added to their stakes in Lyell Immunopharma, 9 trimmed positions, and 22 made no changes.
• Altogether, these fund groups held 12.71Mn shares in LYEL by March 2026, up by 2.51Mn shares quarter on quarter, and up 4.93Mn shares year over year.
• ARCH Venture Management, LLC holds the largest position in LYEL at 3.25Mn shares as of March 31, 2026, or 14.84% of shares outstanding.
• Leading buyers of Lyell Immunopharma shares for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (718.16K), ARCH Venture Management, LLC (488.09K), MILLENNIUM MANAGEMENT LLC (400.25K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (159.18K), Velan Capital Investment Management LP (102.0K).
• The largest sellers of Lyell Immunopharma for the quarter ending March 2026 were Goldman Sachs Group Inc (78.86K), RBF Capital, LLC (60.98K), Barclays Plc (14.3K), TWO SIGMA INVESTMENTS, LP (4.03K), CANADA PENSION PLAN INVESTMENT BOARD (2.7K).
• Business Quant data shows the 10 biggest positions in Lyell Immunopharma as of March 2026 are held by ARCH Venture Management, LLC (3.25Mn), GSK plc (1.51Mn), Foresite Capital Management IV, LLC (800.4K), Orland Properties Ltd (754.7K), VANGUARD CAPITAL MANAGEMENT LLC (718.16K), Decheng Capital LLC (692.05K), Almitas Capital LLC (577.81K), Foresite Capital Management V, LLC (477.08K), MILLENNIUM MANAGEMENT LLC (458.9K), CITADEL ADVISORS LLC (381.46K).